The five potential sources of nitrosamine contamination

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Zakokor)
(Image: Getty/Zakokor)

Related tags: contamination, Recall, Nitrosamine, Ema

With nitrosamines back in the headlines due to the recent discovery of contaminants in ranitidine, the EMA releases the five potential causes of the impurities plaguing the industry.

The European Medicines Agency (EMA) provided information​ to marketing authorization holders (MAHs) on how to evaluate the risk for the formation of nitrosamine impurities in human medicinal products.

The guidance comes after a number of different ‘sartan’-based products were found to be contaminated with nitrosamines​, which was then followed by a separate investigation finding similar impurities in ranitidine medicines​.

In its advice to MAHs, the EMA warned manufacturers that it had identified five main root causes of nitrosamine formation and contamination:

  1. Nitrosamine impurities formed during the processing of active pharmaceuticals ingredients (APIs) under certain processing conditions and with certain raw materials, starting materials, and intermediates present. The agency added that despite later quality control steps, it may not be able to ‘fully purge’ contaminants later in the manufacturing process
  2. The use of sodium nitrite, or other nitrites, in the presence of second or tertiary amines. Secondary amines can be present in reagents and solvents. Tertiary amines can be present in common bases, such as triethylamine and diisopropylethylamine
  3. The use of contaminated raw materials in the manufacturing process, such as recycled solvents, reagents and catalysts – these may pose a risk due to the presence of amines in the waste streams
  4. Using third-parties to recover materials, such as solvents, reagents, and catalysts, which do not receive enough information on the content of the materials and use routine recovery processes with non-dedicated equipment
  5. The use of contaminated starting materials, including intermediates provided by vendors using processes that lead to the formation of nitrosamines

The EMA concluded that MAHs should review their manufacturing processes to identify any of the risks posed in the five points and take action to mitigate the risk.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars